ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies


NCT Number:



Study Status:






with a MMUD using stem cells from a donor’s blood [instead of using the donor’s bone marrow]. An allogeneic stem cell transplant is a standard treatment for blood cancers. An allogeneic transplant replaces your abnormal (or diseased) blood cells with healthy blood-making cells from a donor. We’re doing this study to see how well transplant works in adults with a MMUD using stem cells from a donor’s blood. This study treatment does not include any investigational drugs.

Are you Eligible? (Inclusion Criteria)

  • Donor:
  • 1. Are you 18 year of age or older and younger then 36?
  • 2. Are you willing and able to donate peripheral blood stem cells?
  • Recipient:
  • 1. Are you 18 years of age or older?
  • 2. Have you been diagnosed with any of the following: acute leukemia, MDS,
  • chronic myelogenous leukemia, or lymphoma with chemosensitive disease?
  • 3. Is your liver functional?

Specialty Area(s)

Leukemia, Lymphoma, Multiple Myeloma/Amyloidosis

Principal Investigator

Profile Headshot
  • Director of Translational Research, Blood and Marrow Transplantation Program
  • Director of the Cell Therapy Program

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032